Skip to main content
Top
Published in: Reviews in Endocrine and Metabolic Disorders 4/2021

Open Access 01-12-2021

Inborn errors of metabolism: Lessons from iPSC models

Authors: Rubén Escribá, Raquel Ferrer-Lorente, Ángel Raya

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 4/2021

Login to get access

Abstract

The possibility of reprogramming human somatic cells to pluripotency has opened unprecedented opportunities for creating genuinely human experimental models of disease. Inborn errors of metabolism (IEMs) constitute a greatly heterogeneous class of diseases that appear, in principle, especially suited to be modeled by iPSC-based technology. Indeed, dozens of IEMs have already been modeled to some extent using patient-specific iPSCs. Here, we review the advantages and disadvantages of iPSC-based disease modeling in the context of IEMs, as well as particular challenges associated to this approach, together with solutions researchers have proposed to tackle them. We have structured this review around six lessons that we have learnt from those previous modeling efforts, and that we believe should be carefully considered by researchers wishing to embark in future iPSC-based models of IEMs.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chace DH, Kalas TA, Naylor EW. The application of tandem mass spectrometry to neonatal screening for inherited disorders of intermediary metabolism. Annu Rev Genomics Hum Genet. 2002;3:17–45.PubMedCrossRef Chace DH, Kalas TA, Naylor EW. The application of tandem mass spectrometry to neonatal screening for inherited disorders of intermediary metabolism. Annu Rev Genomics Hum Genet. 2002;3:17–45.PubMedCrossRef
2.
go back to reference Matalonga L, Gort L, Ribes A. Small molecules as therapeutic agents for inborn errors of metabolism. J Inherit Metab Dis. 2017;40(2):177–93.PubMedCrossRef Matalonga L, Gort L, Ribes A. Small molecules as therapeutic agents for inborn errors of metabolism. J Inherit Metab Dis. 2017;40(2):177–93.PubMedCrossRef
3.
go back to reference Haskins M. Gene therapy for lysosomal storage diseases (LSDs) in large animal models. ILAR J. 2009;50(2):112–21.PubMedCrossRef Haskins M. Gene therapy for lysosomal storage diseases (LSDs) in large animal models. ILAR J. 2009;50(2):112–21.PubMedCrossRef
4.
go back to reference Hemsley KM, Hopwood JJ. Lessons learnt from animal models: pathophysiology of neuropathic lysosomal storage disorders. J Inherit Metab Dis. 2010;33(4):363–71.PubMedCrossRef Hemsley KM, Hopwood JJ. Lessons learnt from animal models: pathophysiology of neuropathic lysosomal storage disorders. J Inherit Metab Dis. 2010;33(4):363–71.PubMedCrossRef
5.
go back to reference Pastores GM, Torres PA, Zeng BJ. Animal models for lysosomal storage disorders. Biochemistry (Mosc). 2013;78(7):721–5.CrossRef Pastores GM, Torres PA, Zeng BJ. Animal models for lysosomal storage disorders. Biochemistry (Mosc). 2013;78(7):721–5.CrossRef
6.
go back to reference Wager K, Mahmood F, Russell C. Modelling inborn errors of metabolism in zebrafish. J Inherit Metab Dis. 2014;37(4):483–95.PubMedCrossRef Wager K, Mahmood F, Russell C. Modelling inborn errors of metabolism in zebrafish. J Inherit Metab Dis. 2014;37(4):483–95.PubMedCrossRef
7.
go back to reference Demaret T, et al. Longitudinal study of Pex1-G844D NMRI mouse model: A robust pre-clinical model for mild Zellweger spectrum disorder. Biochim Biophys Acta Mol Basis Dis. 2020;1866(11):165900.PubMedCrossRef Demaret T, et al. Longitudinal study of Pex1-G844D NMRI mouse model: A robust pre-clinical model for mild Zellweger spectrum disorder. Biochim Biophys Acta Mol Basis Dis. 2020;1866(11):165900.PubMedCrossRef
8.
go back to reference Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–76.PubMedCrossRef Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–76.PubMedCrossRef
9.
go back to reference Lee G, Studer L. Induced pluripotent stem cell technology for the study of human disease. Nat Methods. 2010;7(1):25–7.PubMedCrossRef Lee G, Studer L. Induced pluripotent stem cell technology for the study of human disease. Nat Methods. 2010;7(1):25–7.PubMedCrossRef
11.
go back to reference Sanchez-Danes A, et al. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson’s disease. EMBO Mol Med. 2012;4(5):380–95.PubMedPubMedCentralCrossRef Sanchez-Danes A, et al. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson’s disease. EMBO Mol Med. 2012;4(5):380–95.PubMedPubMedCentralCrossRef
12.
go back to reference Matamoros-Angles A, et al. iPS Cell Cultures from a Gerstmann-Straussler-Scheinker Patient with the Y218N PRNP Mutation Recapitulate tau Pathology. Mol Neurobiol. 2018;55(4):3033–48.PubMedCrossRef Matamoros-Angles A, et al. iPS Cell Cultures from a Gerstmann-Straussler-Scheinker Patient with the Y218N PRNP Mutation Recapitulate tau Pathology. Mol Neurobiol. 2018;55(4):3033–48.PubMedCrossRef
13.
go back to reference Takahashi K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–72.PubMedCrossRef Takahashi K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–72.PubMedCrossRef
14.
go back to reference Yu J, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(5858):1917–20.PubMedCrossRef Yu J, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(5858):1917–20.PubMedCrossRef
15.
go back to reference Bonten EJ, et al. Chaperone-mediated gene therapy with recombinant AAV-PPCA in a new mouse model of type I sialidosis. Biochim Biophys Acta. 2013;1832(10):1784–92.PubMedPubMedCentralCrossRef Bonten EJ, et al. Chaperone-mediated gene therapy with recombinant AAV-PPCA in a new mouse model of type I sialidosis. Biochim Biophys Acta. 2013;1832(10):1784–92.PubMedPubMedCentralCrossRef
16.
go back to reference Fog CK, Kirkegaard T. Animal models for Niemann-Pick type C: implications for drug discovery & development. Expert Opin Drug Discov. 2019;14(5):499–509.PubMedCrossRef Fog CK, Kirkegaard T. Animal models for Niemann-Pick type C: implications for drug discovery & development. Expert Opin Drug Discov. 2019;14(5):499–509.PubMedCrossRef
20.
go back to reference Onos KD, et al. Toward more predictive genetic mouse models of Alzheimer’s disease. Brain Res Bull. 2016;122:1–11.PubMedCrossRef Onos KD, et al. Toward more predictive genetic mouse models of Alzheimer’s disease. Brain Res Bull. 2016;122:1–11.PubMedCrossRef
23.
go back to reference Tseng WL, et al. Imbalanced Production of Reactive Oxygen Species and Mitochondrial Antioxidant SOD2 in Fabry Disease-Specific Human Induced Pluripotent Stem Cell-Differentiated Vascular Endothelial Cells. Cell Transplant. 2017;26(3):513–27.PubMedPubMedCentralCrossRef Tseng WL, et al. Imbalanced Production of Reactive Oxygen Species and Mitochondrial Antioxidant SOD2 in Fabry Disease-Specific Human Induced Pluripotent Stem Cell-Differentiated Vascular Endothelial Cells. Cell Transplant. 2017;26(3):513–27.PubMedPubMedCentralCrossRef
24.
go back to reference Volkner C, et al. Pluripotent Stem Cells for Disease Modeling and Drug Discovery in Niemann-Pick Type C1. Int J Mol Sci. 2021;22(2). Volkner C, et al. Pluripotent Stem Cells for Disease Modeling and Drug Discovery in Niemann-Pick Type C1. Int J Mol Sci. 2021;22(2).
25.
go back to reference Seol B, Kim YD, Cho YS. Modeling Sialidosis with Neural Precursor Cells Derived from Patient-Derived Induced Pluripotent Stem Cells. Int J Mol Sci. 2021;22(9). Seol B, Kim YD, Cho YS. Modeling Sialidosis with Neural Precursor Cells Derived from Patient-Derived Induced Pluripotent Stem Cells. Int J Mol Sci. 2021;22(9).
26.
go back to reference Odaka H, et al. An iPSC-based neural model of sialidosis uncovers glycolytic impairment-causing presynaptic dysfunction and deregulation of Ca(2+) dynamics. Neurobiol Dis. 2021;152:105279.PubMedCrossRef Odaka H, et al. An iPSC-based neural model of sialidosis uncovers glycolytic impairment-causing presynaptic dysfunction and deregulation of Ca(2+) dynamics. Neurobiol Dis. 2021;152:105279.PubMedCrossRef
27.
go back to reference Song HY, et al. Reversal of the Inflammatory Responses in Fabry Patient iPSC-Derived Cardiovascular Endothelial Cells by CRISPR/Cas9-Corrected Mutation. Int J Mol Sci. 2021;22(5). Song HY, et al. Reversal of the Inflammatory Responses in Fabry Patient iPSC-Derived Cardiovascular Endothelial Cells by CRISPR/Cas9-Corrected Mutation. Int J Mol Sci. 2021;22(5).
28.
go back to reference Liedtke M, et al. Pathophysiological In Vitro Profile of Neuronal Differentiated Cells Derived from Niemann-Pick Disease Type C2 Patient-Specific iPSCs Carrying the NPC2 Mutations c.58G>T/c.140G>T. Int J Mol Sci. 2021;22(8). Liedtke M, et al. Pathophysiological In Vitro Profile of Neuronal Differentiated Cells Derived from Niemann-Pick Disease Type C2 Patient-Specific iPSCs Carrying the NPC2 Mutations c.58G>T/c.140G>T. Int J Mol Sci. 2021;22(8).
29.
go back to reference Yu D, et al. Niemann-Pick Disease Type C: Induced Pluripotent Stem Cell-Derived Neuronal Cells for Modeling Neural Disease and Evaluating Drug Efficacy. J Biomol Screen. 2014;19(8):1164–73.PubMedPubMedCentralCrossRef Yu D, et al. Niemann-Pick Disease Type C: Induced Pluripotent Stem Cell-Derived Neuronal Cells for Modeling Neural Disease and Evaluating Drug Efficacy. J Biomol Screen. 2014;19(8):1164–73.PubMedPubMedCentralCrossRef
30.
go back to reference Corbett JL, Duncan SA. iPSC-Derived Hepatocytes as a Platform for Disease Modeling and Drug Discovery. Front Med (Lausanne). 2019;6:265.CrossRef Corbett JL, Duncan SA. iPSC-Derived Hepatocytes as a Platform for Disease Modeling and Drug Discovery. Front Med (Lausanne). 2019;6:265.CrossRef
31.
go back to reference Zabulica M, et al. Gene Editing Correction of a Urea Cycle Defect in Organoid Stem Cell Derived Hepatocyte-like Cells. Int J Mol Sci. 2021;22(3). Zabulica M, et al. Gene Editing Correction of a Urea Cycle Defect in Organoid Stem Cell Derived Hepatocyte-like Cells. Int J Mol Sci. 2021;22(3).
32.
go back to reference Shi Y, et al. Induced pluripotent stem cell technology: a decade of progress. Nat Rev Drug Discov. 2017;16(2):115–30.PubMedCrossRef Shi Y, et al. Induced pluripotent stem cell technology: a decade of progress. Nat Rev Drug Discov. 2017;16(2):115–30.PubMedCrossRef
33.
go back to reference Omole AE, Fakoya AOJ. Ten years of progress and promise of induced pluripotent stem cells: historical origins, characteristics, mechanisms, limitations, and potential applications. PeerJ. 2018;6:e4370.PubMedCrossRef Omole AE, Fakoya AOJ. Ten years of progress and promise of induced pluripotent stem cells: historical origins, characteristics, mechanisms, limitations, and potential applications. PeerJ. 2018;6:e4370.PubMedCrossRef
34.
go back to reference Yamashita T, et al. Pharmaceutical Research for Inherited Metabolic Disorders of the Liver Using Human Induced Pluripotent Stem Cell and Genome Editing Technologies. Biol Pharm Bull. 2019;42(3):312–8.PubMedCrossRef Yamashita T, et al. Pharmaceutical Research for Inherited Metabolic Disorders of the Liver Using Human Induced Pluripotent Stem Cell and Genome Editing Technologies. Biol Pharm Bull. 2019;42(3):312–8.PubMedCrossRef
35.
36.
go back to reference Wen Z, et al. Synaptic dysregulation in a human iPS cell model of mental disorders. Nature. 2014;515(7527):414–8.PubMedCrossRef Wen Z, et al. Synaptic dysregulation in a human iPS cell model of mental disorders. Nature. 2014;515(7527):414–8.PubMedCrossRef
37.
go back to reference di Domenico A, et al. Patient-Specific iPSC-Derived Astrocytes Contribute to Non-Cell-Autonomous Neurodegeneration in Parkinson’s Disease. Stem Cell Rep. 2019;12(2):213–29.CrossRef di Domenico A, et al. Patient-Specific iPSC-Derived Astrocytes Contribute to Non-Cell-Autonomous Neurodegeneration in Parkinson’s Disease. Stem Cell Rep. 2019;12(2):213–29.CrossRef
38.
go back to reference Lee G, et al. Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression. Nat Biotechnol. 2012;30(12):1244–8.PubMedPubMedCentralCrossRef Lee G, et al. Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression. Nat Biotechnol. 2012;30(12):1244–8.PubMedPubMedCentralCrossRef
39.
41.
go back to reference Naryshkin NA, et al. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science. 2014;345(6197):688–93.PubMedCrossRef Naryshkin NA, et al. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science. 2014;345(6197):688–93.PubMedCrossRef
42.
go back to reference Mullard A. Stem-cell discovery platforms yield first clinical candidates. Nat Rev Drug Discov. 2015;14(9):589–91.PubMedCrossRef Mullard A. Stem-cell discovery platforms yield first clinical candidates. Nat Rev Drug Discov. 2015;14(9):589–91.PubMedCrossRef
43.
go back to reference Kletzl H, et al. The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy. Neuromuscul Disord. 2019;29(1):21–9.PubMedCrossRef Kletzl H, et al. The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy. Neuromuscul Disord. 2019;29(1):21–9.PubMedCrossRef
44.
go back to reference Campeau PM, Scriver CR, Mitchell JJ. A 25-year longitudinal analysis of treatment efficacy in inborn errors of metabolism. Mol Genet Metab. 2008;95(1–2):11–6.PubMedCrossRef Campeau PM, Scriver CR, Mitchell JJ. A 25-year longitudinal analysis of treatment efficacy in inborn errors of metabolism. Mol Genet Metab. 2008;95(1–2):11–6.PubMedCrossRef
45.
go back to reference Lee H, et al. Pathological roles of the VEGF/SphK pathway in Niemann-Pick type C neurons. Nat Commun. 2014;5:5514.PubMedCrossRef Lee H, et al. Pathological roles of the VEGF/SphK pathway in Niemann-Pick type C neurons. Nat Commun. 2014;5:5514.PubMedCrossRef
46.
go back to reference Rosenbaum AI, et al. Endocytosis of beta-cyclodextrins is responsible for cholesterol reduction in Niemann-Pick type C mutant cells. Proc Natl Acad Sci U S A. 2010;107(12):5477–82.PubMedPubMedCentralCrossRef Rosenbaum AI, et al. Endocytosis of beta-cyclodextrins is responsible for cholesterol reduction in Niemann-Pick type C mutant cells. Proc Natl Acad Sci U S A. 2010;107(12):5477–82.PubMedPubMedCentralCrossRef
47.
go back to reference Pipalia NH, et al. Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts. Proc Natl Acad Sci U S A. 2011;108(14):5620–5.PubMedPubMedCentralCrossRef Pipalia NH, et al. Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts. Proc Natl Acad Sci U S A. 2011;108(14):5620–5.PubMedPubMedCentralCrossRef
48.
go back to reference Wehrmann ZT, et al. Quantitative comparison of the efficacy of various compounds in lowering intracellular cholesterol levels in Niemann-Pick type C fibroblasts. PLoS One. 2012;7(10):e48561.PubMedPubMedCentralCrossRef Wehrmann ZT, et al. Quantitative comparison of the efficacy of various compounds in lowering intracellular cholesterol levels in Niemann-Pick type C fibroblasts. PLoS One. 2012;7(10):e48561.PubMedPubMedCentralCrossRef
49.
go back to reference Tiscornia G, et al. Neuronopathic Gaucher’s disease: induced pluripotent stem cells for disease modelling and testing chaperone activity of small compounds. Hum Mol Genet. 2013;22(4):633–45.PubMedCrossRef Tiscornia G, et al. Neuronopathic Gaucher’s disease: induced pluripotent stem cells for disease modelling and testing chaperone activity of small compounds. Hum Mol Genet. 2013;22(4):633–45.PubMedCrossRef
51.
go back to reference Huang HP, et al. Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification. Hum Mol Genet. 2011;20(24):4851–64.PubMedCrossRef Huang HP, et al. Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification. Hum Mol Genet. 2011;20(24):4851–64.PubMedCrossRef
52.
go back to reference Lemonnier T, et al. Modeling neuronal defects associated with a lysosomal disorder using patient-derived induced pluripotent stem cells. Hum Mol Genet. 2011;20(18):3653–66.PubMedCrossRef Lemonnier T, et al. Modeling neuronal defects associated with a lysosomal disorder using patient-derived induced pluripotent stem cells. Hum Mol Genet. 2011;20(18):3653–66.PubMedCrossRef
53.
go back to reference Higuchi T, et al. The generation of induced pluripotent stem cells (iPSCs) from patients with infantile and late-onset types of Pompe disease and the effects of treatment with acid-alpha-glucosidase in Pompe’s iPSCs. Mol Genet Metab. 2014;112(1):44–8.PubMedCrossRef Higuchi T, et al. The generation of induced pluripotent stem cells (iPSCs) from patients with infantile and late-onset types of Pompe disease and the effects of treatment with acid-alpha-glucosidase in Pompe’s iPSCs. Mol Genet Metab. 2014;112(1):44–8.PubMedCrossRef
54.
go back to reference Raval KK, et al. Pompe disease results in a Golgi-based glycosylation deficit in human induced pluripotent stem cell-derived cardiomyocytes. J Biol Chem. 2015;290(5):3121–36.PubMedCrossRef Raval KK, et al. Pompe disease results in a Golgi-based glycosylation deficit in human induced pluripotent stem cell-derived cardiomyocytes. J Biol Chem. 2015;290(5):3121–36.PubMedCrossRef
55.
go back to reference Sato Y, et al. Disease modeling and lentiviral gene transfer in patient-specific induced pluripotent stem cells from late-onset Pompe disease patient. Mol Ther Methods Clin Dev. 2015;2:15023.PubMedPubMedCentralCrossRef Sato Y, et al. Disease modeling and lentiviral gene transfer in patient-specific induced pluripotent stem cells from late-onset Pompe disease patient. Mol Ther Methods Clin Dev. 2015;2:15023.PubMedPubMedCentralCrossRef
56.
go back to reference Zhang Y, et al. Generation of induced pluripotent stem cells (iPSCs) from an infant with Pompe disease carrying with compound mutations of R608X and E888X in GAA gene. Stem Cell Res. 2019;41:101621.PubMedCrossRef Zhang Y, et al. Generation of induced pluripotent stem cells (iPSCs) from an infant with Pompe disease carrying with compound mutations of R608X and E888X in GAA gene. Stem Cell Res. 2019;41:101621.PubMedCrossRef
57.
go back to reference Cheng YS, et al. A human induced pluripotent stem cell line (TRNDi007-B) from an infantile onset Pompe patient carrying p.R854X mutation in the GAA gene. Stem Cell Res. 2019;37:101435.PubMedPubMedCentralCrossRef Cheng YS, et al. A human induced pluripotent stem cell line (TRNDi007-B) from an infantile onset Pompe patient carrying p.R854X mutation in the GAA gene. Stem Cell Res. 2019;37:101435.PubMedPubMedCentralCrossRef
58.
go back to reference Kajiwara M, et al. Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells. Proc Natl Acad Sci U S A. 2012;109(31):12538–43.PubMedPubMedCentralCrossRef Kajiwara M, et al. Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells. Proc Natl Acad Sci U S A. 2012;109(31):12538–43.PubMedPubMedCentralCrossRef
59.
go back to reference Hu BY, et al. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc Natl Acad Sci U S A. 2010;107(9):4335–40.PubMedPubMedCentralCrossRef Hu BY, et al. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc Natl Acad Sci U S A. 2010;107(9):4335–40.PubMedPubMedCentralCrossRef
60.
go back to reference Baker DE, et al. Adaptation to culture of human embryonic stem cells and oncogenesis in vivo. Nat Biotechnol. 2007;25(2):207–15.PubMedCrossRef Baker DE, et al. Adaptation to culture of human embryonic stem cells and oncogenesis in vivo. Nat Biotechnol. 2007;25(2):207–15.PubMedCrossRef
61.
go back to reference Lee CT, et al. Functional consequences of 17q213.1/WNT3-WNT9B amplification in hPSCs with respect to neural differentiation. Cell Rep. 2015;10(4):616–32.PubMedPubMedCentralCrossRef Lee CT, et al. Functional consequences of 17q213.1/WNT3-WNT9B amplification in hPSCs with respect to neural differentiation. Cell Rep. 2015;10(4):616–32.PubMedPubMedCentralCrossRef
63.
go back to reference Howden SE, et al. Genetic correction and analysis of induced pluripotent stem cells from a patient with gyrate atrophy. Proc Natl Acad Sci U S A. 2011;108(16):6537–42.PubMedPubMedCentralCrossRef Howden SE, et al. Genetic correction and analysis of induced pluripotent stem cells from a patient with gyrate atrophy. Proc Natl Acad Sci U S A. 2011;108(16):6537–42.PubMedPubMedCentralCrossRef
65.
go back to reference Frank S, Skryabin BV, Greber B. A modified TALEN-based system for robust generation of knock-out human pluripotent stem cell lines and disease models. BMC Genomics. 2013;14:773.PubMedPubMedCentralCrossRef Frank S, Skryabin BV, Greber B. A modified TALEN-based system for robust generation of knock-out human pluripotent stem cell lines and disease models. BMC Genomics. 2013;14:773.PubMedPubMedCentralCrossRef
66.
go back to reference Garate Z, et al. Generation of a High Number of Healthy Erythroid Cells from Gene-Edited Pyruvate Kinase Deficiency Patient-Specific Induced Pluripotent Stem Cells. Stem Cell Rep. 2015;5(6):1053–66.CrossRef Garate Z, et al. Generation of a High Number of Healthy Erythroid Cells from Gene-Edited Pyruvate Kinase Deficiency Patient-Specific Induced Pluripotent Stem Cells. Stem Cell Rep. 2015;5(6):1053–66.CrossRef
67.
go back to reference Maetzel D, et al. Genetic and chemical correction of cholesterol accumulation and impaired autophagy in hepatic and neural cells derived from Niemann-Pick Type C patient-specific iPS cells. Stem Cell Rep. 2014;2(6):866–80.CrossRef Maetzel D, et al. Genetic and chemical correction of cholesterol accumulation and impaired autophagy in hepatic and neural cells derived from Niemann-Pick Type C patient-specific iPS cells. Stem Cell Rep. 2014;2(6):866–80.CrossRef
68.
go back to reference Yang J, et al. Generation of Human Liver Chimeric Mice with Hepatocytes from Familial Hypercholesterolemia Induced Pluripotent Stem Cells. Stem Cell Rep. 2017;8(3):605–18.CrossRef Yang J, et al. Generation of Human Liver Chimeric Mice with Hepatocytes from Familial Hypercholesterolemia Induced Pluripotent Stem Cells. Stem Cell Rep. 2017;8(3):605–18.CrossRef
70.
go back to reference Omer L, et al. CRISPR Correction of a Homozygous Low-Density Lipoprotein Receptor Mutation in Familial Hypercholesterolemia Induced Pluripotent Stem Cells. Hepatol Commun. 2017;1(9):886–98.PubMedPubMedCentralCrossRef Omer L, et al. CRISPR Correction of a Homozygous Low-Density Lipoprotein Receptor Mutation in Familial Hypercholesterolemia Induced Pluripotent Stem Cells. Hepatol Commun. 2017;1(9):886–98.PubMedPubMedCentralCrossRef
71.
go back to reference Okada H, et al. Function and Immunogenicity of Gene-corrected iPSC-derived Hepatocyte-Like Cells in Restoring Low Density Lipoprotein Uptake in Homozygous Familial Hypercholesterolemia. Sci Rep. 2019;9(1):4695.PubMedPubMedCentralCrossRef Okada H, et al. Function and Immunogenicity of Gene-corrected iPSC-derived Hepatocyte-Like Cells in Restoring Low Density Lipoprotein Uptake in Homozygous Familial Hypercholesterolemia. Sci Rep. 2019;9(1):4695.PubMedPubMedCentralCrossRef
72.
go back to reference Omer L, et al. Familial hypercholesterolemia class II low-density lipoprotein receptor response to statin treatment. Dis Model Mech. 2020;13(4). Omer L, et al. Familial hypercholesterolemia class II low-density lipoprotein receptor response to statin treatment. Dis Model Mech. 2020;13(4).
73.
go back to reference Birket MJ, et al. A Human Stem Cell Model of Fabry Disease Implicates LIMP-2 Accumulation in Cardiomyocyte Pathology. Stem Cell Rep. 2019;13(2):380–93.CrossRef Birket MJ, et al. A Human Stem Cell Model of Fabry Disease Implicates LIMP-2 Accumulation in Cardiomyocyte Pathology. Stem Cell Rep. 2019;13(2):380–93.CrossRef
74.
go back to reference Do HS, et al. Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells. EBioMedicine. 2020;52:102633.PubMedPubMedCentralCrossRef Do HS, et al. Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells. EBioMedicine. 2020;52:102633.PubMedPubMedCentralCrossRef
75.
go back to reference Allende ML, et al. Cerebral organoids derived from Sandhoff disease-induced pluripotent stem cells exhibit impaired neurodifferentiation. J Lipid Res. 2018;59(3):550–63.PubMedPubMedCentralCrossRef Allende ML, et al. Cerebral organoids derived from Sandhoff disease-induced pluripotent stem cells exhibit impaired neurodifferentiation. J Lipid Res. 2018;59(3):550–63.PubMedPubMedCentralCrossRef
76.
go back to reference Beneto N, et al. Neuronal and Astrocytic Differentiation from Sanfilippo C Syndrome iPSCs for Disease Modeling and Drug Development. J Clin Med. 2020;9(3). Beneto N, et al. Neuronal and Astrocytic Differentiation from Sanfilippo C Syndrome iPSCs for Disease Modeling and Drug Development. J Clin Med. 2020;9(3).
77.
go back to reference Hayashi H, et al. Modeling Human Bile Acid Transport and Synthesis in Stem Cell-Derived Hepatocytes with a Patient-Specific Mutation. Stem Cell Rep. 2021;16(2):309–23.CrossRef Hayashi H, et al. Modeling Human Bile Acid Transport and Synthesis in Stem Cell-Derived Hepatocytes with a Patient-Specific Mutation. Stem Cell Rep. 2021;16(2):309–23.CrossRef
78.
go back to reference Eglen R, Reisine T. Primary cells and stem cells in drug discovery: emerging tools for high-throughput screening. Assay Drug Dev Technol. 2011;9(2):108–24.PubMedCrossRef Eglen R, Reisine T. Primary cells and stem cells in drug discovery: emerging tools for high-throughput screening. Assay Drug Dev Technol. 2011;9(2):108–24.PubMedCrossRef
79.
go back to reference Zuba-Surma EK, et al. Stem cells as a novel tool for drug screening and treatment of degenerative diseases. Curr Pharm Des. 2012;18(18):2644–56.PubMedCrossRef Zuba-Surma EK, et al. Stem cells as a novel tool for drug screening and treatment of degenerative diseases. Curr Pharm Des. 2012;18(18):2644–56.PubMedCrossRef
81.
go back to reference Chanana AM, Rhee JW, Wu JC. Human-induced pluripotent stem cell approaches to model inborn and acquired metabolic heart diseases. Curr Opin Cardiol. 2016;31(3):266–74.PubMedPubMedCentralCrossRef Chanana AM, Rhee JW, Wu JC. Human-induced pluripotent stem cell approaches to model inborn and acquired metabolic heart diseases. Curr Opin Cardiol. 2016;31(3):266–74.PubMedPubMedCentralCrossRef
82.
83.
go back to reference Long Y, et al. Induced Pluripotent Stem Cells for Disease Modeling and Evaluation of Therapeutics for Niemann-Pick Disease Type A. Stem Cells Transl Med. 2016;5(12):1644–55.PubMedPubMedCentralCrossRef Long Y, et al. Induced Pluripotent Stem Cells for Disease Modeling and Evaluation of Therapeutics for Niemann-Pick Disease Type A. Stem Cells Transl Med. 2016;5(12):1644–55.PubMedPubMedCentralCrossRef
84.
go back to reference Soga M, et al. HPGCD outperforms HPBCD as a potential treatment for Niemann-Pick disease type C during disease modeling with iPS cells. Stem Cells. 2015;33(4):1075–88.PubMedCrossRef Soga M, et al. HPGCD outperforms HPBCD as a potential treatment for Niemann-Pick disease type C during disease modeling with iPS cells. Stem Cells. 2015;33(4):1075–88.PubMedCrossRef
85.
go back to reference Sima N, et al. Neural stem cells for disease modeling and evaluation of therapeutics for infantile (CLN1/PPT1) and late infantile (CLN2/TPP1) neuronal ceroid lipofuscinoses. Orphanet J Rare Dis. 2018;13(1):54.PubMedPubMedCentralCrossRef Sima N, et al. Neural stem cells for disease modeling and evaluation of therapeutics for infantile (CLN1/PPT1) and late infantile (CLN2/TPP1) neuronal ceroid lipofuscinoses. Orphanet J Rare Dis. 2018;13(1):54.PubMedPubMedCentralCrossRef
86.
88.
89.
go back to reference Brown RA, et al. mTOR hyperactivity mediates lysosomal dysfunction in Gaucher's disease iPSC-neuronal cells. Dis Model Mech. 2019;12(10). Brown RA, et al. mTOR hyperactivity mediates lysosomal dysfunction in Gaucher's disease iPSC-neuronal cells. Dis Model Mech. 2019;12(10).
90.
go back to reference Cayo MA, et al. A Drug Screen using Human iPSC-Derived Hepatocyte-like Cells Reveals Cardiac Glycosides as a Potential Treatment for Hypercholesterolemia. Cell Stem Cell. 2017;20(4):478-489e5.PubMedPubMedCentralCrossRef Cayo MA, et al. A Drug Screen using Human iPSC-Derived Hepatocyte-like Cells Reveals Cardiac Glycosides as a Potential Treatment for Hypercholesterolemia. Cell Stem Cell. 2017;20(4):478-489e5.PubMedPubMedCentralCrossRef
91.
go back to reference Jing R, et al. A Screen Using iPSC-Derived Hepatocytes Reveals NAD(+) as a Potential Treatment for mtDNA Depletion Syndrome. Cell Rep. 2018;25(6):1469-1484e5.PubMedPubMedCentralCrossRef Jing R, et al. A Screen Using iPSC-Derived Hepatocytes Reveals NAD(+) as a Potential Treatment for mtDNA Depletion Syndrome. Cell Rep. 2018;25(6):1469-1484e5.PubMedPubMedCentralCrossRef
92.
go back to reference Kajihara R, et al. Novel Drug Candidates Improve Ganglioside Accumulation and Neural Dysfunction in GM1 Gangliosidosis Models with Autophagy Activation. Stem Cell Rep. 2020;14(5):909–23.CrossRef Kajihara R, et al. Novel Drug Candidates Improve Ganglioside Accumulation and Neural Dysfunction in GM1 Gangliosidosis Models with Autophagy Activation. Stem Cell Rep. 2020;14(5):909–23.CrossRef
93.
go back to reference Ruillier V, et al. Rescuing compounds for Lesch-Nyhan disease identified using stem cell-based phenotypic screening. JCI Insight. 2020;5(4). Ruillier V, et al. Rescuing compounds for Lesch-Nyhan disease identified using stem cell-based phenotypic screening. JCI Insight. 2020;5(4).
94.
go back to reference Zeltner N, Studer L. Pluripotent stem cell-based disease modeling: current hurdles and future promise. Curr Opin Cell Biol. 2015;37:102–10.PubMedCrossRef Zeltner N, Studer L. Pluripotent stem cell-based disease modeling: current hurdles and future promise. Curr Opin Cell Biol. 2015;37:102–10.PubMedCrossRef
95.
go back to reference Calatayud C, et al. Modeling the genetic complexity of Parkinson’s disease by targeted genome edition in iPS cells. Curr Opin Genet Dev. 2017;46:123–31.PubMedCrossRef Calatayud C, et al. Modeling the genetic complexity of Parkinson’s disease by targeted genome edition in iPS cells. Curr Opin Genet Dev. 2017;46:123–31.PubMedCrossRef
96.
go back to reference Avior Y, Sagi I, Benvenisty N. Pluripotent stem cells in disease modelling and drug discovery. Nat Rev Mol Cell Biol. 2016;17(3):170–82.PubMedCrossRef Avior Y, Sagi I, Benvenisty N. Pluripotent stem cells in disease modelling and drug discovery. Nat Rev Mol Cell Biol. 2016;17(3):170–82.PubMedCrossRef
97.
go back to reference Canals I, et al. Activity and High-Order Effective Connectivity Alterations in Sanfilippo C Patient-Specific Neuronal Networks. Stem Cell Rep. 2015;5(4):546–57.CrossRef Canals I, et al. Activity and High-Order Effective Connectivity Alterations in Sanfilippo C Patient-Specific Neuronal Networks. Stem Cell Rep. 2015;5(4):546–57.CrossRef
98.
go back to reference Chen YF, et al. Rapid generation of mature hepatocyte-like cells from human induced pluripotent stem cells by an efficient three-step protocol. Hepatology. 2012;55(4):1193–203.PubMedCrossRef Chen YF, et al. Rapid generation of mature hepatocyte-like cells from human induced pluripotent stem cells by an efficient three-step protocol. Hepatology. 2012;55(4):1193–203.PubMedCrossRef
99.
go back to reference Feric NT, Radisic M. Maturing human pluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissues. Adv Drug Deliv Rev. 2016;96:110–34.PubMedCrossRef Feric NT, Radisic M. Maturing human pluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissues. Adv Drug Deliv Rev. 2016;96:110–34.PubMedCrossRef
100.
go back to reference Pampaloni F, Reynaud EG, Stelzer EH. The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol. 2007;8(10):839–45.PubMedCrossRef Pampaloni F, Reynaud EG, Stelzer EH. The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol. 2007;8(10):839–45.PubMedCrossRef
101.
go back to reference Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science. 2014;345(6194):1247125.PubMedCrossRef Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science. 2014;345(6194):1247125.PubMedCrossRef
102.
go back to reference Duval K, et al. Modeling Physiological Events in 2D vs. 3D Cell Culture. Physiology (Bethesda). 2017;32(4):266–77. Duval K, et al. Modeling Physiological Events in 2D vs. 3D Cell Culture. Physiology (Bethesda). 2017;32(4):266–77.
103.
go back to reference Akbari S, et al. Robust, Long-Term Culture of Endoderm-Derived Hepatic Organoids for Disease Modeling. Stem Cell Rep. 2019;13(4):627–41.CrossRef Akbari S, et al. Robust, Long-Term Culture of Endoderm-Derived Hepatic Organoids for Disease Modeling. Stem Cell Rep. 2019;13(4):627–41.CrossRef
104.
go back to reference Winanto, et al. Organoid cultures of MELAS neural cells reveal hyperactive Notch signaling that impacts neurodevelopment. Cell Death Dis. 2020;11(3):182. Winanto, et al. Organoid cultures of MELAS neural cells reveal hyperactive Notch signaling that impacts neurodevelopment. Cell Death Dis. 2020;11(3):182.
105.
go back to reference Inak G, et al. Defective metabolic programming impairs early neuronal morphogenesis in neural cultures and an organoid model of Leigh syndrome. Nat Commun. 2021;12(1):1929.PubMedPubMedCentralCrossRef Inak G, et al. Defective metabolic programming impairs early neuronal morphogenesis in neural cultures and an organoid model of Leigh syndrome. Nat Commun. 2021;12(1):1929.PubMedPubMedCentralCrossRef
106.
go back to reference Sances S, et al. Human iPSC-Derived Endothelial Cells and Microengineered Organ-Chip Enhance Neuronal Development. Stem Cell Rep. 2018;10(4):1222–36.CrossRef Sances S, et al. Human iPSC-Derived Endothelial Cells and Microengineered Organ-Chip Enhance Neuronal Development. Stem Cell Rep. 2018;10(4):1222–36.CrossRef
108.
go back to reference Wang G, et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat Med. 2014;20(6):616–23.PubMedPubMedCentralCrossRef Wang G, et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat Med. 2014;20(6):616–23.PubMedPubMedCentralCrossRef
109.
Metadata
Title
Inborn errors of metabolism: Lessons from iPSC models
Authors
Rubén Escribá
Raquel Ferrer-Lorente
Ángel Raya
Publication date
01-12-2021
Publisher
Springer US
Published in
Reviews in Endocrine and Metabolic Disorders / Issue 4/2021
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-021-09671-z

Other articles of this Issue 4/2021

Reviews in Endocrine and Metabolic Disorders 4/2021 Go to the issue